Biovica International AB (publ) have received a new patent in Japan. The patent refers to Biovica's method of measuring thymidine kinase activity on a real-time PCR platform. The new patent is valid until 13th of May 2031. With this patent, Biovica has received patent protection for the PCR-based product on all 16 markets the company has applied for patent protection.
”It is important for Biovica to protect our unique technology. Hence, it is positive news that we get improved patent protection on one of the more important markets. Patent protection is important in order to be able to bring our products to the market to contribute to best possible treatment for cancer patients.”, says Anders Rylander, CEO Biovica.